ArticleOrphanet journal of rare diseases2025

Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey.

Ari Zimran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.